This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2002 Jun;138(6):740-2.

doi: 10.1001/archderm.138.6.740.

Denileukin diftitox for the treatment of panniculitic lymphoma

Karen S McGinnis¹, Michael Shapiro, Jacqueline M Junkins-Hopkins, Mitchell Smith, Stuart R Lessin, Carmela C Vittorio, Alain H Rook

Affiliations

PMID: 12056952
DOI: 10.1001/archderm.138.6.740

Case Reports

Denileukin diftitox for the treatment of panniculitic lymphoma

Karen S McGinnis et al. Arch Dermatol. 2002 Jun.

. 2002 Jun;138(6):740-2.

doi: 10.1001/archderm.138.6.740.

Authors

Karen S McGinnis¹, Michael Shapiro, Jacqueline M Junkins-Hopkins, Mitchell Smith, Stuart R Lessin, Carmela C Vittorio, Alain H Rook

Affiliation

¹ arook@mail.med.upenn.edu

PMID: 12056952
DOI: 10.1001/archderm.138.6.740

No abstract available

PubMed Disclaimer

Similar articles

Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma.
Hathaway T, Subtil A, Kuo P, Foss F. Hathaway T, et al. Clin Lymphoma Myeloma. 2007 Sep;7(8):541-5. doi: 10.3816/clm.2007.n.040. Clin Lymphoma Myeloma. 2007. PMID: 18021473
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Duvic M, et al. Clin Lymphoma. 2002 Mar;2(4):222-8. doi: 10.3816/clm.2002.n.003. Clin Lymphoma. 2002. PMID: 11970761 Clinical Trial.
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M. Talpur R, et al. J Invest Dermatol. 2006 Mar;126(3):575-83. doi: 10.1038/sj.jid.5700122. J Invest Dermatol. 2006. PMID: 16410787
Denileukin diftitox.
Figgitt DP, Lamb HM, Goa KL. Figgitt DP, et al. Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008. Am J Clin Dermatol. 2000. PMID: 11702307 Review.
Immunomodulatory effects of rexinoids.
Foss F. Foss F. Semin Oncol. 2006 Feb;33(1 Suppl 3):S21-5. doi: 10.1053/j.seminoncol.2005.12.019. Semin Oncol. 2006. PMID: 16516672 Review.

See all similar articles

Cited by

Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ. Kreitman RJ. BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001. BioDrugs. 2009. PMID: 19344187 Free PMC article. Review.
Toxin-based therapeutic approaches.
Shapira A, Benhar I. Shapira A, et al. Toxins (Basel). 2010 Nov;2(11):2519-83. doi: 10.3390/toxins2112519. Epub 2010 Oct 28. Toxins (Basel). 2010. PMID: 22069564 Free PMC article. Review.
Tumor-stromal interactions in pancreatic cancer.
Whatcott C, Han H, Posner RG, Von Hoff DD. Whatcott C, et al. Crit Rev Oncog. 2013;18(1-2):135-51. doi: 10.1615/critrevoncog.v18.i1-2.80. Crit Rev Oncog. 2013. PMID: 23237556 Free PMC article. Review.
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Mehta N, Wayne AS, Kim YH, Hale GA, Alvarado CS, Myskowski P, Jaffe ES, Busam KJ, Pulitzer M, Zwerner J, Horwitz S. Mehta N, et al. Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):20-5. doi: 10.1016/j.clml.2011.06.016. Epub 2011 Oct 15. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22001256 Free PMC article.
Treatment relapsed subcutaneous panniculitis-like T-cell lymphoma together HPS by Cyclosporin A.
Chen R, Liu L, Liang YM. Chen R, et al. Hematol Rep. 2010 Jan 26;2(1):e9. doi: 10.4081/hr.2010.e9. Epub 2010 Nov 30. Hematol Rep. 2010. PMID: 22184522 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information